Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Vaginal cancer
Stage/Subtype:  recurrent vaginal cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-9 of 9 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 150005, 15-C-0005, NCT02280811
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120116, 12-C-0116, NCT01585428
Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ATDTRPST0802, NCT00800345
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110061, 11-C-0061, NCT01273168
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-A-007-13, NCT01831089
Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0655, NCT02045368
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4190C00010, NCT02261220
Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-211, NCT02308241
Start Over